AMD patients respond to aflibercept treatment

Article

A study recently published in the British Journal of Ophthalmology found that patients with exudative age-related macular degeneration (AMD) who were incomplete responders to multiple ranibizumab injections (Lucentis, Genentech) saw improvements with aflibercept (Eylea, Regeneron) treatment.

A study recently published in the British Journal of Ophthalmology found that patients with exudative age-related macular degeneration (AMD) who were incomplete responders to multiple ranibizumab injections (Lucentis, Genentech) saw improvements with aflibercept (Eylea, Regeneron) treatment.

Eylea receives FDA approval for DME treatment

The study aimed to determine the efficacy of 2.0 mg aflibercept in the management of patients with recalcitrant exudative AMD. Patients were seen monthly and were given the aflibercept treatment at baseline, and at months one, two, and four. Retreatment was given at months three and five as needed based on SD-OCT. After six months, researchers looked at the mean change in Early Treatment Diabetic Retinopathy Study best corrected visual acuity (ETDRS BCVA) and central subfield thickness (CST); mean number of aflibercept injections; percentage of PRN injections required, patients with no fluid on SD-OCT, and patients losing fewer than 15 letters.

According to researchers, the study found that aflibercept 2.0 mg treatment maintained mean visual acuity improvements previously achieved with high-dose 2.0-mg ranibizumab injections in recalcitrant wet AMD patients. The treatment led to significant anatomic improvement and was required monthly in most patients.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Carolyn Majcher, OD, FAAO, detailed a talk she gave alongside Mary Beth Yackey, OD, at Optometry's Meeting 2025.
Alongside Rachel Steele, OD, Rafieetary outlines what to look for in blurred disc margins and the importance of acting fast and sending patients to the ED when needed.
Rachelle Lin, OD, MS, FAAO, on collaborating more effectively on neovascular retinal cases
Dr Luke Lindsell discusses retinal therapy and geographic atrophy at Controversies in Modern Eye Care 2025
CIME 25: Dilsher Dhoot, MD, FASRS, is excited about emerging retinal therapies.
Steven Ferrucci, OD, FAAO, at Controversies in Modern Eyecare 2025
CRU 2025 provided the latest insights regarding glaucoma, dry eye disease, retina, myopia, neurotrophic keratitis, and keratoconus.
Rachelle Lin, OD, MS, FAAO
Rachelle Lin, OD, MS, FAAO, at CRU Eye Symposium 2025
Rachelle Lin, OD, MS, FAAO, details her presentation on inherited retinal diseases at CRU 2025.
© 2025 MJH Life Sciences

All rights reserved.